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Background: Gemcitabine has evolved as standard therapy in advanced pancreatic cancer since the demon-
stration of a significant clinical benefit. Phase II trials have shown that gemcitabine can be successfully
combined with thymidylate synthase (TS) inhibitors such as continuous-infusion 5-fluorouracil (5-FU). How-
ever, continuous-infusion 5-FU is inconvenient because of the need for a central venous access. The aim of this
study was to assess the efficacy and safety of gemcitabine in combination with raltitrexed (Tomudex), a novel
and selective TS inhibitor that has the advantage of a 3-weekly treatment interval and manageable toxicity.
Patients and methods: Chemotherapy-naïve patients with measurable advanced pancreatic cancer were
treated with raltitrexed 3 mg/m2 as a 15-min infusion on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8,
every 21 days.
Results: Twenty-five eligible patients (17 male, eight female) with metastatic (21 patients) or locally
advanced (four patients) disease entered the study. The median number of courses per patient was four (range
1–14). One patient was not evaluable for response. There were three partial remissions [12%; 95% confidence
interval (CI) 2.6% to 31.2%] and nine stable disease situations (36%; 95% CI 18.0% to 57.5%), while the
tumours of 12 patients (48%; 95% CI 27.8% to 68.7%) showed progressive disease after three treatment
cycles. WHO grade 3/4 toxicity was rare and symptomatic in only one patient, who experienced grade 4
diarrhoea and grade 3 nausea and vomiting. Symptomatic benefit was seen in 12 patients. Median survival was
185 days (95% CI 129–241) with six patients still alive.
Conclusions: The efficacy of raltitrexed plus gemcitabine is limited, but compares well with other chemo-
therapy treatment options in advanced pancreatic cancer. However, this combination is convenient and
symptomatic toxicity is rare. Thus, raltitrexed and gemcitabine should be investigated further in combination
with drugs interfering with specific molecular targets.
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Introduction
The study of Burris et al. [1] has established gemcitabine as
standard treatment for advanced pancreatic cancer. Gemcitabine
has not only shown a survival benefit but also an improvement
of various disease-related symptoms over bolus 5-fluorouracil
(5-FU). However, the effect of gemcitabine on measurable dis-
ease was rather limited since objective tumour responses were
observed in only three out of 56 patients (5.4%). A beneficial
effect of 5-FU per se cannot be excluded from this trial. The
efficacy of fluoropyrimidines is highly schedule-dependent and
weekly bolus administration might not be the optimal schedule.
A phase II study with continuous-infusion 5-FU in advanced pan-
creatic cancer has shown an objective response rate of 19% and
disease stabilisation in half of the patients [2]. Although different
schedules of 5-FU administration have not been formally com-
pared in pancreatic cancer, these results suggest that continuous
infusion might be more effective than weekly bolus adminis-
tration in this disease.
Two recently published studies in advanced pancreatic cancer
have shown a 19–20% objective response rate and a clinical
benefit in patients undergoing treatment with the combination
gemcitabine plus continuous-infusion 5-FU [3, 4]. Despite a
favourable toxicity profile, this treatment is not convenient, since
continuous 5-FU necessitates the use of a permanent central
venous access and a portable pump system. The major molecular
target for the activity of 5-FU is thymidylate synthase (TS),
which is inhibited by 5-FU alone and more efficiently by the
combination 5-FU plus leucovorin [5]. Raltitrexed is a new
selective TS inhibitor, which has the advantage of a 3-weekly
treatment interval and low toxicity. Randomised phase III studies
in advanced colorectal cancer have proven similar efficacy but
significantly lower toxicity of raltitrexed compared with bio-
modulated 5-FU [6].
Given alone, raltitrexed has shown a response rate of 5% in
pancreatic cancer [7], which compares well with the activity of
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gemcitabine in this disease [1]. Raltitrexed and gemcitabine are
attractive partners for combination treatment because of the non-
overlapping toxicity profile of the two drugs. The objective of
this trial was to assess activity and tolerability of the combination
raltitrexed and gemcitabine in chemotherapy-naïve patients with
non-resectable, advanced or metastatic pancreatic cancer. Both
drugs were administered at the doses used for single-agent
treatment to allow for maximum dose intensity. This was a
single-centre study and patients could be closely monitored for
unforeseen toxicity.
Patients and methods
Patient eligibility
Chemotherapy-naïve patients with advanced non-resectable adenocarcinoma
of the pancreas were entered into this single-centre phase II study between
September 1999 and June 2001. Eligibility criteria included cytologically or
histologically confirmed adenocarcinoma of the pancreas, two-dimensionally
measurable disease by computed tomography (CT) scan, and a WHO
performance status of two or less. Patients were older than 18 years of age and
had an estimated life expectancy of at least 12 weeks. Adequate organ func-
tion was defined as white blood cell count ≥3500/µl, platelet count ≥100 000/
µl, total bilirubin ≤35 µmol/l, and serum creatinine level ≤140 µmol/l. The
study was submitted to the local ethics committee and written informed
consent was obtained from all patients before study entry.
Treatment plan
Raltitrexed (Tomudex; AstraZeneca, Zug, Switzerland) was administered at
a dose of 3 mg/m2 over 15 min on day 1 of a 2-day treatment cycle. In cases
of moderate renal dysfunction, the dose of raltitrexed was adapted. If the
creatinine clearance was 55–65 ml/min, 75% of the planned dose was
administered, and if the creatinine clearance was 25–54 ml/min only 50% of
the dose was administered. In addition, the cycle duration was extended to
4 weeks in cases of moderate renal dysfunction. When the creatinine clear-
ance was <25 ml/min, raltitrexed was stopped and the patient went off study.
Gemcitabine [Gemzar; Eli Lilly (Suisse) SA, Vernier, Switzerland] was
administered at a dose of 1000 mg/m2 over 30 min on days 1 and 8 of a 21-day
treatment cycle. If the treatment cycle duration was extended because of renal
dysfunction, gemcitabine was also given on day 15.
The start of a treatment cycle was postponed in case of WHO grade
>1 toxicity. After a delay of more then 3 weeks, the patient went off study.
The raltitrexed dose was reduced to 75 or 50%, respectively, if grade 3 (2) or
grade 4 (3) (non)-haematological toxicity occurred in the previous treatment
cycle. In the case of grade 4 non-haematological toxicity, the patient went off
study. Gemcitabine was omitted in the case of grade ≥3 haematological and
grade ≥2 non-haematological toxicity on day 8 (or 15). The gemcitabine dose
was reduced to 75%, if grade 3 non-haematological or grade 4 haematological
toxicity occurred in the previous treatment cycle.
Follow-up procedures and response evaluation
Blood counts were obtained weekly. Chemistry profiles including CA 19-9
antigen and physical examinations were done every 3 weeks. The first CT
reassessment for response evaluation was performed at 9 weeks. Partial
response (PR) was defined as ≥50% decrease in the sum of the products of
two perpendicular diameters of all measurable lesions. In cases of responsive
disease (PR or stable disease), the response had to be verified at least 4 weeks
after the last CT scan.
Statistical methods
For the calculation of the required sample size, we used the MinMax two-
stage design [8] with the following assumptions. A response rate of 15% was
considered insufficient to allow further accrual into this study. A response
rate of 30% was deemed interesting in view of the other treatment options in
this disease stage. According to the Simon MinMax two-stage method with a
type II error (1-β) of 80% and a type I error (α) of 5%, the combination of
gemcitabine and raltitrexed was to be considered uninteresting in terms of
efficacy if three responses or fewer were observed in the first 23 patients,
or 11 responses or fewer in the first 48 patients.
Overall survival was determined as the time interval from day 1 of
treatment until death. Survival was calculated by the Kaplan–Meier product-
limit method [9].
Results
Twenty-six patients were entered in this study. One patient was
considered ineligible because of the lack of measurable lesions
and one patient did not receive any therapy because of fast clin-
ical deterioration. The baseline characteristics of the 25 evaluable
patients are summarised in Table 1. A total of 134 treatment
cycles were administered (median four, range 1–14). Four patients
received only one treatment cycle mainly because of early dis-
ease progression. One patient refused therapy after one cycle
because of nausea and grade 2 anaemia. Over the first four treat-
ment cycles, dose modifications for toxicity were performed in
12% of the patients. Raltitrexed dose reduction for renal impair-
ment was necessary in four patients, whereas dose re-escalation
was possible in two patients. In six patients, the raltitrexed dose
was not adapted as detailed in the protocol for impaired renal
Table 1. Patient characteristics
WHO, World Health Organization.
Characteristic n
Number of patients 25
Age (years)
Median 63
Range 41–77
Female/male 8/17
WHO performance status
0 5
1 18
2 2
WHO pain intensity
0 7
1 17
2 1
>5% body weight loss pretreatment 16
Disease at presentation
Locally advanced 4
Metastastic 21
More than one metastatic site 10
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function at a creatinine clearance of 49–60 ml/min because of
protocol violation. Four of these patients experienced grade 2
haematological toxicity, one patient in combination with grade 2
diarrhoea. One patient erroneously received raltitrexed on day 8
in addition to day 1. He was hospitalised immediately and treated
prophylactically with intravenous leucovorin and subcutaneous
granulocyte colony-stimulating factor. After eventless recovery,
the protocol treatment was continued.
Toxicity
For all patients, toxicity of up to six treatment cycles was
evaluated and the results are summarised in Table 2. The most
important toxicity was anaemia. However, grade 1/2 anaemia
was pre-existing in 70% of the patients. Six patients required
blood transfusions. In 85% of cycles the haemoglobin remained
stable at day 1 of the treatment cycles or rose during treatment.
Grade 3/4 leukopenia was rare and was not complicated by fever
and infections in any patient. Thrombocytopenia was also a rare
side-effect and occurred only in cases where the raltitrexed dose
was not adapted according to the reduced creatinine clearance.
Elevated transaminases and alkaline phosphatase were fre-
quently observed in these patients. However, these abnormalities
were pre-existing in most of the cases and more probably disease-
associated than treatment-related. Grade 1/2 nausea occurred in
26% of the treatment cycles, whereas vomiting was observed in
only 12% of the cycles. Diarrhoea emerged in 10% of all cycles.
Grade 4 diarrhoea occurred in one patient, leading to hospital-
isation at the end of the second cycle. The recovery was unevent-
ful. However, treatment had to be stopped because of tumour
progression.
Efficacy
Three of the 25 chemotherapy-treated patients achieved a lasting
PR for a response rate of 12% [95% confidence interval (CI)
2.6% to 31.2%]. All these responses were radiologically verified
after at least 1 month of continuing treatment. One additional
patient with liver metastases experienced a radiological PR and a
drop of the marker CA 19-9 from 250 to 74 kU/l. However, this
response was not radiologically confirmed, since the clinical
status of the patient deteriorated rapidly within 6 weeks. Thirty-
six percent (95% CI 18.0% to 57.5%) of the patients experienced
disease stabilisation or a minor response lasting 3–10 months. In
48% (95% CI 27.8% to 68.7%) of the patients the tumour was
progressive despite treatment.
Results of CA 19-9 measurements were available in 23 patients.
This tumour marker decreased in all of the responding patients
and began to increase as a reflection of disease progression one
or two cycles before radiological documentation of progression
or clinical deterioration in all cases. In only one patient did
the marker decrease despite radiological disease progression
(Figure 1).
Eighteen patients reported pain and 20 patients had a reduced
performance status at study entry. Pain could be reduced in 77%
of the patients for at least one cycle on study treatment without
intensification of the pain medication. In 38% of these patients,
the pain medication could be reduced without pain intensifi-
cation. Five patients could stabilise their weight, seven continued
loosing weight and seven gained a median of 2 kg on study. Most
of these clinical improvements occurred after two or three treat-
ment cycles. Of patients receiving more than one treatment cycle,
64% improved or stabilised their performance status.
The median follow-up for the patients still alive was 353 days
(range 270–675). The median overall survival from study entry
for all eligible patients was 185 days (95% CI 129–241)
(Figure 2). Six patients are still alive at 270, 295, 338, 368, 590
and 675 days follow-up. Six-month survival was 50%, 9-month
survival 23% and 1-year survival 12%. Three patients are still on
trial.
Table 2. Toxicity
Values are the number of patients with each toxicity (only highest toxicity grade per patient included) and 
in parentheses, the number of cycles with the toxicity (95 treatment cycles evaluated).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; WHO, World Health Organization.
Toxicity WHO grade
1 2 3 4
Nausea 9 (19) 5 (6) 2 (2) –
Diarrhoea 4 (8) 2 (2) – 1 (1)
Cutaneous 4 (5) – – –
Leukopenia 6 (9) 5 (14) 2 (4) 1 (1)
Anaemia 8 (58) 12 (22) 2 (2) –
Thrombocytopenia 3 (3) 2 (3) 2 (2) –
Elevated AST/ALT 3 (36) 3 (7) 8 (10) 1 (1)
Elevated alkaline phosphatase 12 (47) 3 (14) 5 (9) –
Elevated bilirubin 3 (3) – 1 (1) –
Ankle oedema 7 (15) – – –
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Discussion
Progress in the treatment of advanced pancreatic cancer has been
slow. The only study to demonstrate a clinical benefit of one
chemotherapy over another has established gemcitabine as the
standard single-agent treatment in this disease [1]. However, a
non-optimal 5-FU schedule was used in the comparator arm of
the trial and a 5% response rate and 23-week survival duration
with gemcitabine alone leave much room for improvement.
Other modern anticancer drugs such as paclitaxel, docetaxel,
topotecan or irinotecan seem not to have major single-agent
activity, based on the results of well-conducted phase II studies
[10–14]. Disappointingly, median survival duration has generally
remained below 6 months with all available agents.
Considering the clinically most relevant median survival end
point, various chemotherapy combinations have suggested a
slight improvement compared with single-agent treatment. Com-
bining gemcitabine with cisplatin or oxaliplatin has translated
into a median survival duration of 7.4–9+ months [15–18].
However, this apparent superiority of combination treatment has
been derived from the results of non-comparative trials and it is
possible that the slight improvement seen with combination treat-
ment is mainly because of better patient selection. It is well
known that extent of disease and performance status are major
prognostic factors for survival, even in the absence of treatment
[19]. Thus, until the results of well-performed randomised trials
comparing single-agent with combination treatment are avail-
able, it is not clear whether the additional costs and toxicity of
combinations are outweighed by significant clinical benefit. This
is even more true in the light of recent results with novel drug
combinations such as docetaxel plus cisplatin, docetaxel plus
gemcitabine, pemetrexed plus gemcitabine or oxaliplatin plus
gemcitabine [20–22]. Even in probably highly selected phase II
study populations, these combinations have resulted in disap-
pointing median survival durations of 5.7–7.6 months.
So far, no randomised study has proven a clear advantage of
combination chemotherapy over single-agent treatment in
advanced pancreatic cancer. Adding mitomycin C to protracted
venous infusion 5-FU has led to a significantly improved
response rate without translating into a survival benefit. No
symptomatic and quality-of-life improvement was observed with
the combination treatment. Two recently reported studies have
investigated the impact of combining 5-FU with standard gem-
Figure 1. CA 19-9 evolution during trial treatment.
Figure 2. Overall survival.
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citabine. A randomised phase II study from an Italian group
found no survival benefit if gemcitabine was combined with
continuous-infusion 5-FU. The study was presented after 89
evaluable patients had been entered. A more mature trial of the
Eastern Cooperative Oncology Group has randomised 327
patients. The results of this trial favour combination treatment,
although the survival difference is not statistically significant
(P = 0.11). Again, 5-FU has not been used in the most promising
continuous-infusion schedule.
Two phase II studies have shown a median survival of 6.7–
7.2 months and a clinical benefit in patients undergoing treatment
with the combination gemcitabine plus continuous-infusion 5-FU
[3, 4]. Although the toxicity profile was favourable, this treat-
ment is not convenient since continuous 5-FU necessitates the
use of a permanent central venous access and a portable pump
system. The recent availability of oral fluoropyrimidine drugs
such as uracil/tegafur or capecitabine has helped to circumvent
this problem. A phase I study by Herrmann et al. [23] has tested
the combination of capecitabine and gemcitabine in advanced
pancreatic cancer. The recommended dose for capecitabine from
this trial was 1300 mg/m2 daily for 14 days every 3 weeks, which
is nearly half of the recommended single-agent dose for this drug.
Thus, there are considerations that capecitabine was underdosed
in this study [24]. Currently, this regimen is being compared with
gemcitabine alone in an international randomised phase III study
(R. Herrmann, personal communication). Scheithauer et al. [25]
have recently presented the preliminary results of a similar study
suggesting no efficacy benefit of the capecitabine plus gem-
citabine combination over gemcitabine alone. Again, the chosen
dose regimen for the fluoropyrimidine drug was not standard,
since capecitabine was only given for 7 days per cycle instead of
the more common 14-day or continuous administration schedule.
In terms of survival and clinical benefit, the combination
raltitrexed and gemcitabine compares well with other combin-
ations of gemcitabine and TS inhibitors in the treatment of
advanced pancreatic cancer. Our study population was not a
good-prognosis selection, as most patients had metastatic as
compared with locally advanced disease. This is an important
issue in assessing clinical studies of advanced pancreatic cancer,
since the overall survival in metastatic disease is significantly
worse than in locally advanced disease [19]. In our study, a
significant proportion of patients reported decreasing pain
intensity and analgesic consumption, a better performance status
and increasing weight with protocol treatment. Quality-of-life
issues are very important in chemotherapy treatment of advanced
pancreatic cancer in view of the fact that even new agents and
drug combinations have not yet translated into better median
survival results than 6–8 months. Thus, the major advantage of
the combination raltitrexed and gemcitabine is its favourable
toxicity profile and the convenience of administration. Symptom-
atic side-effects are very rare, with a minority of patients
experiencing nausea or diarrhoea. Stomatitis or the hand–foot
syndrome have not been observed in our study population. The
TS inhibitor raltitrexed can be given as a short infusion once
every 3 weeks and the use of infusion pumps or the prolonged
intake of several tablets per day is not necessary.
Clearly, the efficacy of the gemcitabine and raltitrexed
combination leaves much room for improvement. This combin-
ation should not be routinely used outside clinical trials until it
has been formally tested against other therapeutic options in
advanced pancreatic cancer. However, because of its conven-
ience and favourable toxicity profile, it is an eligible combination
partner for other active agents. As novel compounds interfering
with specific biological targets such as the epidermal growth
factor signalling pathway, angiogenesis or apoptosis regulation
enter the clinic, it will be advantageous to combine these agents
with minimally toxic chemotherapy drug partners.
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